PTIX.US Protagenic Therapeutics

Healthcare Biotechnology USA Stocks
0.4500 USD
Close of Nov 17, 2026
0.1280 2.38
Market cap
USD 815K
P/E
0.2x
P/B
3.35x
ROE
-291.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is PTIX.US undervalued?

Graham number

The Graham number of Protagenic Therapeutics cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Protagenic Therapeutics fundamental analysis

No fundamental analysis for Protagenic Therapeutics yet.

Protagenic Therapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.

Full company profile